Promising QuickMIC® data from two US study sites will be presented at ASM Microbe 2024
The diagnostics company Gradientech today announces that data from the successfully completed US pre-clinical evaluation of QuickMIC® will be presented at the ASM Microbe conference in Atlanta, Georgia, June 13th-17th.
Organised by the American Society of Microbiology, ASM Microbe is one of the largest microbial sciences conferences in the US, bringing together thousands of scientists, researchers, and healthcare professionals. The event consists of keynote sessions, interactive workshops, and poster presentations, with cutting-edge topics ranging from how to use AI to design new antibiotics to presentation of novel diagnostic technologies. Rapid antibiotic susceptibility testing (AST) features prominently in the scientific program, where for example M.D. Daniel Rhoads will give an overview of AST technology in his talk “A Quick Take on Rapid AST” (June 15th 10:45-11.30 AM), and Prof. April Bobenchick will outline the impact of these new technologies in her talk “The Impact of Rapid Diagnostics on Antimicrobial Stewardship Practices” (June 13th, 2:00 – 2:45 PM).
“Following the large number of presentations on the QuickMIC system at the ESCMID Global conference earlier this spring, we are pleased to see the first US scientific data on QuickMIC being presented at ASM Microbe. The fact that the data from both studies were accepted for presentation is reflective of the strong US interest in rapid AST,” says Marc van Nuenen, VP Business Development US at Gradientech.
”I am very proud to see the promising progress we are making in the US and grateful for the high interest to collaborate with Gradientech to significantly improve sepsis patient care,” says Sara Thorslund, co-founder and CEO at Gradientech.
QuickMIC® studies presented at ASM Microbe
|
Abstract title |
Presentation details |
|
Evaluation of a Novel Rapid AST Assay for the Determination of MICs of Gram-Negative Organisms from Positive Blood Cultures within 4 Hours of Bottle Positivity, Nicole van Zeeland et.al. |
Poster session Date: June 15th Time: 10:00 AM – 5:00 PM |
|
Evaluation of the Gradientech QuickMIC System for Phenotypic Antimicrobial Susceptibility Testing on Positive Blood Cultures, Logan Patterson et. al. |
Oral session |
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO Marc van Nuenen, VP Business Development US
Tel: +46 736 29 35 80 Tel: +1 919 808 7190
sara.thorslund@gradientech.se marc.vannuenen@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
